Robotic Biologist Unravels Complex Problems
|
By LabMedica International staff writers Posted on 27 Oct 2011 |
Computers are now capable of automating the scientific process itself. An interdisciplinary group of scientists has taken a major step toward this objective by demonstrating that a computer can analyze unprocessed research data from a biologic system and derive the basic mathematical equations that describe the way the system operates.
According to the researchers, from Vanderbilt University (Nashville, TN, USA), Cornell University (Ithaca, NY, USA), and CFD Research Corp., Inc. (Huntsville, AL, USA), it is one of the most complicated scientific modeling hurdles that a computer has solved totally from scratch.
The article that described this accomplishment was published in the October 2011 issue of the journal Physical Biology and it is available online. The work was a collaboration between John P. Wikswo, a professor at Vanderbilt, Dr. Michael Schmidt, and Dr. Hod Lipson at the Creative Machines Lab at Cornell University, and Dr. Jerry Jenkins and Dr. Ravishankar Vallabhajosyula at CFDRC.
The system’s “brains,” which Prof. Wikswo has termed the Automated Biology Explorer (ABE), is in a novel piece of software called Eureqa, developed at Cornell and released in 2009. Drs. Schmidt and Lipson originally created Eureqa to design robots without going through the typical trial and error stage that is both slow and expensive. After it succeeded, they recognized that it could also be applied to solving science problems.
One of Eureqa’s initial achievements was identifying the fundamental laws of motion by studying the motion of a double pendulum, which Eureqa accomplished in a few hours when running on a personal computer (PC).
In 2006, Prof. Wikswo heard Dr. Lipson lecture about his research. “I had a ‘eureka moment’ of my own when I realized the system Hod had developed could be used to solve biological problems and even control them,” Prof. Wikswo said. Thus, he started talking to Dr. Lipson immediately after the lecture and they began a collaboration to adapt Eureqa to analyze biologic problems.
“Biology is the area where the gap between theory and data is growing the most rapidly,” said Dr. Lipson. “So it is the area in greatest need of automation.”
The biologic system that the researchers employed to assess ABE is glycolysis, the basic process that generates energy in a living cell. They focused particularly on the way in which yeast cells control fluctuations in the chemical compounds produced by the process. The researchers chose this specific system, called glycolytic oscillations, to perform a virtual test of the software because it is one of the most extensively studied biologic control systems. Dr. Jenkins and Dr. Vallabhajosyula used one of the processes’ detailed mathematical models to generate a data set corresponding to the measurements a scientist would make under various conditions. To increase the accuracy of the test, the researchers packed the data with a 10% random error. When they fed the data into Eureqa, it derived a set of equations that were almost identical to the known equations. “What’s really amazing is that it produced these equations a priori,” said Dr. Vallabhajosyula. “The only thing the software knew in advance was addition, subtraction, multiplication, and division.”
The capability to generate mathematical equations from scratch is what differentiates ABE from Adam, the robot scientist developed by Dr. Ross King and his colleagues at the University of Wales at Aberystwyth (UK).
Dr. Adam runs yeast genetics experiments and made international headlines two years ago by making a unique scientific discovery without direct human input. King fed Adam with a model of yeast metabolism and a database of genes and proteins involved in metabolism in other species. He also linked the computer to a remote-controlled genetics laboratory. This allowed the computer to generate hypotheses, then devise and conduct actual experiments to test them.
In order to give ABE the ability to run research such as Adam, Prof. Wikswo’s group is currently designing “laboratory-on-a-chip” technology that can be controlled by Eureqa. This will allow ABE to design and perform a wide range of basic biology experiments. Their first endeavor is focused on developing a microfluidics device that can assess cell metabolism.
“Generally, the way that scientists design experiments is to vary one factor at a time while keeping the other factors constant, but, in many cases, the most effective way to test a biological system may be to tweak a large number of different factors at the same time and see what happens. ABE will let us do that,” Prof. Wikswo said.
Related Links:
Vanderbilt University
Cornell University
CFD Research
According to the researchers, from Vanderbilt University (Nashville, TN, USA), Cornell University (Ithaca, NY, USA), and CFD Research Corp., Inc. (Huntsville, AL, USA), it is one of the most complicated scientific modeling hurdles that a computer has solved totally from scratch.
The article that described this accomplishment was published in the October 2011 issue of the journal Physical Biology and it is available online. The work was a collaboration between John P. Wikswo, a professor at Vanderbilt, Dr. Michael Schmidt, and Dr. Hod Lipson at the Creative Machines Lab at Cornell University, and Dr. Jerry Jenkins and Dr. Ravishankar Vallabhajosyula at CFDRC.
The system’s “brains,” which Prof. Wikswo has termed the Automated Biology Explorer (ABE), is in a novel piece of software called Eureqa, developed at Cornell and released in 2009. Drs. Schmidt and Lipson originally created Eureqa to design robots without going through the typical trial and error stage that is both slow and expensive. After it succeeded, they recognized that it could also be applied to solving science problems.
One of Eureqa’s initial achievements was identifying the fundamental laws of motion by studying the motion of a double pendulum, which Eureqa accomplished in a few hours when running on a personal computer (PC).
In 2006, Prof. Wikswo heard Dr. Lipson lecture about his research. “I had a ‘eureka moment’ of my own when I realized the system Hod had developed could be used to solve biological problems and even control them,” Prof. Wikswo said. Thus, he started talking to Dr. Lipson immediately after the lecture and they began a collaboration to adapt Eureqa to analyze biologic problems.
“Biology is the area where the gap between theory and data is growing the most rapidly,” said Dr. Lipson. “So it is the area in greatest need of automation.”
The biologic system that the researchers employed to assess ABE is glycolysis, the basic process that generates energy in a living cell. They focused particularly on the way in which yeast cells control fluctuations in the chemical compounds produced by the process. The researchers chose this specific system, called glycolytic oscillations, to perform a virtual test of the software because it is one of the most extensively studied biologic control systems. Dr. Jenkins and Dr. Vallabhajosyula used one of the processes’ detailed mathematical models to generate a data set corresponding to the measurements a scientist would make under various conditions. To increase the accuracy of the test, the researchers packed the data with a 10% random error. When they fed the data into Eureqa, it derived a set of equations that were almost identical to the known equations. “What’s really amazing is that it produced these equations a priori,” said Dr. Vallabhajosyula. “The only thing the software knew in advance was addition, subtraction, multiplication, and division.”
The capability to generate mathematical equations from scratch is what differentiates ABE from Adam, the robot scientist developed by Dr. Ross King and his colleagues at the University of Wales at Aberystwyth (UK).
Dr. Adam runs yeast genetics experiments and made international headlines two years ago by making a unique scientific discovery without direct human input. King fed Adam with a model of yeast metabolism and a database of genes and proteins involved in metabolism in other species. He also linked the computer to a remote-controlled genetics laboratory. This allowed the computer to generate hypotheses, then devise and conduct actual experiments to test them.
In order to give ABE the ability to run research such as Adam, Prof. Wikswo’s group is currently designing “laboratory-on-a-chip” technology that can be controlled by Eureqa. This will allow ABE to design and perform a wide range of basic biology experiments. Their first endeavor is focused on developing a microfluidics device that can assess cell metabolism.
“Generally, the way that scientists design experiments is to vary one factor at a time while keeping the other factors constant, but, in many cases, the most effective way to test a biological system may be to tweak a large number of different factors at the same time and see what happens. ABE will let us do that,” Prof. Wikswo said.
Related Links:
Vanderbilt University
Cornell University
CFD Research
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







